secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001193125-24-018713
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports $424M cash; ziftomenib combo achieves 100% CR in newly diagnosed AML
--------------------------------------------------------------------------------

- Preliminary unaudited cash $424M as of Dec 31, 2023; net proceeds from private placement $146M.
- Phase 1 KOMET-007: 5 newly diagnosed patients on ziftomenib+7+3 all achieved CR (100%).
- R/R patients on ziftomenib+ven/aza: ORR 53% (8/15); CR/CRh 56% in menin inhibitor-naïve.
- No differentiation syndrome, QTc prolongation, or DLTs observed; well-tolerated.
- Expects to complete KOMET-001 enrollment by mid-2024; cash runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524018713/0001193125-24-018713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524018713/d686268d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-018713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer